Completed OBSERVATIONAL NCT01632878

Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study

Omacor Plus Standard Therapies In Post MI Subjects Evaluation: The OPTIMISE Study

Sponsor: EBC - Evidence Based Communication

Updated 8 times since 2017 Last updated: Mar 18, 2022 Started: Jul 31, 2012 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01632878, this observational or N/A phase trial focuses on Myocardial Infarction (MI) and remains completed. Sponsored by EBC - Evidence Based Communication, it has been updated 8 times since 2012, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Apr 2022 — Jul 2024 [monthly]

Completed
Dec 2021 — Apr 2022 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EBC - Evidence Based Communication
Mylan Inc.
inVentiv Health Germany GmbH

Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Plovdiv, Bulgaria